Bank of America
CUE icon

Bank of America’s Cue Biopharma CUE Stock Holding History

Bank of America’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.6K Buy
6,924
+5
+0.1% +$47 ﹤0.01% 5609
2025
Q4 		$63.3K Sell
6,919
-3,898
-36% -$71.6K ﹤0.01% 5763
2025
Q3 		$233K Sell
10,817
-2
-0% -$47 ﹤0.01% 6205
2025
Q2 		$221K Buy
10,819
+7
+0.1% +$149 ﹤0.01% 6134
2025
Q1 		$295K Buy
10,812
+1
+0% +$37 ﹤0.01% 5949
2024
Q4 		$354K Buy
10,811
+2,838
+36% +$107K ﹤0.01% 5793
2024
Q3 		$181K Sell
7,973
-113
-1% -$2.45K ﹤0.01% 6059
2024
Q2 		$301K Sell
8,086
-35
-0.4% -$1.73K ﹤0.01% 5660
2024
Q1 		$460K Sell
8,121
-753
-8% -$53.1K ﹤0.01% 5403
2023
Q4 		$703K Buy
8,874
+2,585
+41% +$185K ﹤0.01% 5258
2023
Q3 		$434K Buy
6,289
+1,183
+23% +$116K ﹤0.01% 5411
2023
Q2 		$559K Sell
5,106
-477
-9% -$56.1K ﹤0.01% 5212
2023
Q1 		$598K Buy
5,583
+2,349
+73% +$224K ﹤0.01% 5258
2022
Q4 		$277K Sell
3,234
-550
-15% -$50.3K ﹤0.01% 5745
2022
Q3 		$253K Buy
3,784
+2,907
+331% +$250K ﹤0.01% 5844
2022
Q2 		$65K Sell
877
-2,186
-71% -$256K ﹤0.01% 6704
2022
Q1 		$449K Sell
3,063
-773
-20% -$164K ﹤0.01% 5914
2021
Q4 		$1.3M Buy
3,836
+2,773
+261% +$1.07M ﹤0.01% 4994
2021
Q3 		$464K Buy
1,063
+62
+6% +$21.6K ﹤0.01% 5706
2021
Q2 		$350K Sell
1,001
-480
-32% -$186K ﹤0.01% 5691
2021
Q1 		$542K Buy
1,481
+533
+56% +$219K ﹤0.01% 5293
2020
Q4 		$356K Sell
948
-140
-13% -$55.9K ﹤0.01% 5232
2020
Q3 		$491K Sell
1,088
-37
-3% -$21.3K ﹤0.01% 4732
2020
Q2 		$827K Buy
1,125
+522
+87% +$378K ﹤0.01% 4252
2020
Q1 		$257K Buy
603
+195
+48% +$94.5K ﹤0.01% 4938
2019
Q4 		$194K Sell
408
-29
-7% -$9.11K ﹤0.01% 5659
2019
Q3 		$111K Buy
437
+21
+5% +$5.04K ﹤0.01% 5998
2019
Q2 		$112K Buy
416
+101
+32% +$25.1K ﹤0.01% 5950
2019
Q1 		$74K Sell
315
-176
-36% -$33.5K ﹤0.01% 6026
2018
Q4 		$69K Buy
491
+358
+269% +$65K ﹤0.01% 6087
2018
Q3 		$36K Buy
133
+31
+30% +$8.96K ﹤0.01% 6335
2018
Q2 		$37K Buy
102
+80
+364% +$31.8K ﹤0.01% 6284
2018
Q1 		$9K Buy
+22
New +$10K ﹤0.01% 6632

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Bank of America's CUE Position: Q1 2026 in Review

Bank of America increased its Cue Biopharma (CUE) stake by 0.07% in Q1 2026, buying an estimated $47 and bringing the position to 6,924 shares worth $47.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5609.

Bank of America first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.3M in Q4 2021. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Bank of America held 6,924 shares of Cue Biopharma worth $47.6K as of Q1 2026.
  • Bank of America bought 5 Cue Biopharma shares in Q1 2026, an estimated $47.
  • Cue Biopharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5609 holding.
  • Bank of America first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
  • Bank of America's Cue Biopharma position peaked at $1.3M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.